#4 - Johnson & Johnson (NYSE:JNJ)
In January 2022, Johnson & Johnson (NYSE:JNJ) made a list of stocks to buy from Goldman Sachs (NYSE:GS). The sole criteria were to find stocks that had showcased pricing power over the last five years. This isn’t a surprise to investors in JNJ stock, who have been rewarded with a workmanlike 34% gain over that same span.
The company has a portfolio of products that are essential for many consumers. But many investors may be surprised at the expanse of the company’s portfolio, which includes pharmaceutical products as well as the medical technology (Medtech) sectors.
Johnson & Johnson is the second dividend king on this list. The company has increased its dividend every year for the last 61 years. As of July 2022, it has a dividend payout ratio of over 60%. That suggests that investors should have no cause for concern that the company will continue to increase its dividend over time.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Read More - Current Price
- $145.38
- Consensus Rating
- Hold
- Ratings Breakdown
- 5 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $174.07 (19.7% Upside)
